drugset / Trial / NCT07846683
A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3
Not yet recruiting
350 enrolled
Hoffmann-La Roche
Chugai Pharmaceutical · collabPfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of subcutaneous induction with afimkibart in participants with moderately to severely active ulcerative colitis (UC).
Timeline
- Start
- 2026-11-15
- Primary completion
- 2028-05-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afimkibart | Monoclonal antibody | — | Subcutaneous |